Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease.

Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, Feeney C, Horvath R, Yu-Wai-Man P, Chinnery PF, Taylor RW, Turnbull DM, McFarland R. · 2015

Read Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. by Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, Feeney C, Horvath R, Yu-Wai-Man P, Chinnery PF, Taylor RW, Turnbull DM, McFarland R. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4737121.txt.

Introduction

Gráinne S. Gorman, Andrew M. Schaefer, Yi Ng, and nine colleagues counted adult mitochondrial disease in the Annals of Neurology in 2015. Mitochondrial disorders, caused by faults in either the mitochondrial genome or nuclear genes, were thought common but had resisted firm counting because symptoms and genetics vary so much. The team assessed every adult referred with suspected mitochondrial disease in the North East of England over more than two decades, and computed minimum prevalence for 2011.

Mitochondrial DNA mutations sat at about one in five thousand people, matching earlier estimates. Nuclear mutations added roughly three per hundred thousand adults with clear disease. Combined, about one in forty-three hundred adults carries disease-causing mitochondrial faults, putting these disorders among the commonest inherited neurological conditions of adulthood. The authors stress the planning consequences: services, trials, and health policy must budget for a burden this size.

Catalog record

CREATORGorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, Feeney C, Horvath R, Yu-Wai-Man P, Chinnery PF, Taylor RW, Turnbull DM, McFarland R.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE28 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4737121

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease By Gráinne S Gorman, Andrew M Schaefer, Yi Ng, Nicholas Gomez, Emma L Blakely, Charlotte L Alston, Catherine Feeney, Rita Horvath, Patrick Yu‐Wai‐Man, Patrick F Chinnery, Robert W Taylor, Douglass M Turnbull Published in: Annals of Neurology DOI: 10.1002/ana.24362 ABSTRACT Abstract Objective The prevalence of mitochondrial disease has proven difficult to establish, predominantly as a result of clinical and genetic heterogeneity. The phenotypic spectrum of mitochondrial disease has expanded significantly since the original reports that associated classic clinical syndromes with mitochondrial DNA (mtDNA) rearrangements and point mutations. The revolution in genetic technologies has allowed interrogation of the nuclear genome in a manner that has dramatically improved the diagnosis of mitochondrial disorders. We comprehensively assessed the prevalence of all forms of adult mitochondrial disease to include pathogenic mutations in both nuclear and mtDNA. Methods Adults with suspected mitochondrial disease in the North East of England were referred to a single neurology center from 1990 to 2014. For the midyear period of 2011, we evaluated the minimum prevalence of symptomatic nuclear DNA mutations and symptomatic and asymptomatic mtDNA mutations causing mitochondrial diseases. Results The minimum prevalence rate for mtDNA mutations was 1 in 5,000 (20 per 100,000), comparable with our previously published prevalence rates. In this population, nuclear mutations were responsible for clinically overt adult mitochondrial disease in 2.9 per 100,000 adults. Interpretation Combined, our data confirm that the total prevalence of adult mitochondrial disease, including pathogenic mutations of both the mitochondrial and nuclear genomes (≈1 in 4,300), is among the commonest adult forms of inherited neurological disorders. These figures hold important implications for the evaluation of interventions, provision of evidence‐based health policies, and planning of future services. Ann Neurol 2015 Ann Neurol 2015;77:753–759 Mitochondrial disorders are frequently multisystemic in nature and cause significant morbidity and mortality.1, 2 Unfortunately, to date, there are few effective treatments and no known cure. The overall disease burden is potentially extensive, resulting in substantial direct and indirect health care costs to the patient and society as a whole. To date, little is known of the true epidemiological burden of mitochondrial disease. Yet such information will have substantial implications for evaluation of interventions, provision of evidence‐based health policies, and planning of future services for this chronic condition. Accurate assessment of mitochondrial disease prevalence has proven difficult in the past. Meticulous clinical and biochemical characterization of patients remains fundamental to diagnostic yield. Yet diverse and expanding clinical features, variable genotype–phenotype correlates, and the complex structure of referral pathways have all impeded attempts to gauge the true epidemiological impact of mitochondrial disease. Recent advances in diagnostic techniques in tandem with streamlining of referral pathways in the United Kingdom and deployment of extensive family tracing have improved case ascertainment and permitted, for the first time, recording of the minimum prevalence of adult mitochondrial disease, to include pathogenic mutations in both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). SUBJECTS AND METHODS Adult cases (>16 years old) with suspected mitochondrial disease were ascertained following referral to a single specialist mitochondrial center in the North East of England between 1990 and 2011. Referral patterns to this center are drawn mainly from tertiary neurology and neuro‐ophthalmology sources, but historical links with other specialties likely to encounter mitochondrial disease (diabetes, renal, cardiac, and audiology clinics) account for other common routes of referral. The Newcastle Mitochondrial Centre is among only 3 highly specialized, national referral centers for mitochondrial disease in the United Kingdom. Those individuals with pathogenic mtDNA or nDNA mutations, or those with unidentified nuclear mutations, but pathological multiple mtDNA deletions evident in muscle, who were alive at the midyear period of 2011, were identified. Those with multiple mtDNA deletions in muscle were only included when there was no evidence of other muscle pathology, the mtDNA deletions had been independently verified using 2 different techniques (long‐range polymerase chain reaction [PCR], Southern blot or real‐time PCR), and the clinical and biochemical (>3% cyclooxygenase‐deficient fibers) features were consistent with a diagnosis of mitochondrial disease. Affected individuals were included if they lived within the geographical boundary of the North East of England government office region that is defined by 6 postcodes (NE, DH, DL, SR, TS, and TD) and includes County Durham, Northumberland, Newcastle upon Tyne, Sunderland, North Tyneside, Gateshead, Stockton‐on‐Tees, South Tyneside, Middlesbrough, Redcar and Cleveland, Darlington, and Hartlepool. Comprehensive pedigree analysis and family tracing was performed, identifying other clinically affected individuals and also unaffected family members at risk of disease. In contrast to our previous study,3 improvements in noninvasive testing4, 5 have allowed us to include elderly individuals, beyond working age, where a positive genetic diagnosis was confirmed. Ascertainment of Clinically Affected Adults with Disease Due to mtDNA Point Mutations, Deletions, or Duplications, or nDNA Mutations Adopting our previous ascertainment criteria,3 adults exhibiting signs and symptoms consistent with a confirmed molecular genetic diagnosis of mitochondrial disease in either the individual or their pedigree were defined as clinically affected. Whenever possible, a molecular genetic diagnosis was confirmed in several tissues including blood, urine, or muscle using established quantitative techniques described in detail elsewhere.4, 5 Ascertainment of Individuals at Risk for Development of mtDNA Disease Comprehensive pedigree data were collected from all affected individuals, to define individuals at risk for development of mitochondrial disease. We included both adults and children, as previously reported,3 and again restricted our evaluation to first‐degree relatives of those patients with definite clinical disease or asymptomatic individuals known to harbor a familial pathogenic mutation of mtDNA. Molecular genetic analysis was confirmed whenever possible. Statistical Analysis Population census data for the midyear period of 2011, as specified by the Office for National Statistics (ONS) of the United Kingdom,6 was used to derive denominators and calculate the minimum prevalence of both mtDNA and nDNA disease in adult individuals and the minimum prevalence of unaffected individuals at risk of developing mtDNA mitochondrial disease. Ninety‐five percent confidence limits were calculated for each of these groups as described elsewhere.7 RESULTS Prevalence of Pathogenic Mutations of Either mtDNA or nDNA The minimum point prevalence of clinically affected adults with mitochondrial disease attributable to either the mitochondrial or nuclear genome is 12.5 in 100,000 (95% confidence interval (CI) = 11.1–14.1 × 10−5), whereas the prevalence of all pathogenic mutations in both nDNA and mtDNA is 23 in 100,000 (≈1 in 4,300; 95% CI = 14.6–34.5 × 10−5). Clinically Affected Individuals with mtDNA Disease The regional adult population (>16 years old) figure for midyear 2011 was 2,134,449,6 representing a 2.2% increase in the prevalence data denominator over the preceding decade, since our last epidemiological evaluation of the prevalence of mtDNA disorders only. This was relative to an approximately 7% national average change in UK population size.8 Clinically affected adults with mtDNA mutations (n = 204) were identified, determining a minimum point prevalence of 9.6 in 100,000 (95% CI = 8.3–11.0 × 10−5), in this population (Table 1). Seventy‐eight adults (minimum prevalence = 3.7 × 10−5, 95% CI = 2.9–4.6 × 10−5) were affected by 1 of the 3 common Leber hereditary optic neuropathy (LHON)9 pathogenic mutations: m.1178G>A (n = 43, minimum prevalence = 2.0 × 10−5, 95% CI = 1.5–2.7 × 10−5), m.3460G>A (n = 29, minimum prevalence = 1.4

Read the complete text